Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis

Launched by HAUKELAND UNIVERSITY HOSPITAL · Feb 22, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a supplement called Nicotinamide Riboside (NR) to see if it can help slow down the progression of disability in people with progressive multiple sclerosis (MS). The main goal is to determine if taking NR can help patients maintain their abilities and improve their quality of life over a period of 30 months.

To participate in this study, individuals should be between 18 and 65 years old and have a confirmed diagnosis of progressive MS. They should also have experienced some progression of their disability in the past two years. Participants will either receive NR or a placebo (a non-active treatment) and will be monitored throughout the study. It’s important to note that this trial is currently recruiting participants, and those interested should check to see if they meet the eligibility criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • A diagnosis of progressive MS (secondary; SPMS or primary; PPMS) according to the 2013 revisions of clinical course of multiple sclerosis and the 2017 revisions of the McDonald criteria.
• • Aged 18-65 years.
• • EDSS 3-6.5
• • Able to perform T25FW test
• • The participant must have documented evidence of disability progression observed during the 24 months before screening.
• • With or without a stable disease modifying therapy during the last three months.
• • Written informed consent for study participation.
• Exclusion Criteria:
• • A diagnosis of relapsing MS according to the revisions of the McDonald criteria
• • Neoplastic disease at baseline
• • Previous history of malignant melanoma or breast cancer
• • Stable phase of a progressive disease course
• • Pregnancy or lactating female patients
• • Dementia or other neurodegenerative disorder at baseline visit
• • Comorbidity (psychiatric or somatic) that precludes study participation
• • Use of high dose vitamin B3 supplementation within 30 days of enrolment
• • Genetically confirmed mitochondrial disease or metabolic disorder